Table 3.
Distribution of CD66b + TANs in gastric carcinoma
| Amount CD66b + TAN in overall collective (n = 458) | Amount CD66b + TAN in primary surgery cohort (n = 268) | Amount CD66b + TAN in neoadjuvant cohort (n = 190) | ||||
|---|---|---|---|---|---|---|
| Low | High | Low | High | Low | High | |
| Sex | ||||||
| Male | 150 (48.4%) | 160 (51.6%) | 82 (46.6%) | 94 (53.4%) | 68 (50.7%) | 66 (49.3%) |
| Female | 80 (54.1%) | 68 (45.9%) | 49 (53.3%) | 43 (46.7%) | 31 (55.4%) | 25 (44.6%) |
| Age | ||||||
| < 50 | 30 (51.7%) | 28 (48.3%) | 13 (54.2%) | 11 (45.8%) | 17 (50.0%) | 17 (50.0%) |
| > 50 | 187 (49.7%) | 189 (50.3%) | 115 (48.3%) | 123 (51.7%) | 72 (52.2%) | 66 (47.8%) |
| UICC stage | ||||||
| (y)1 | 25 (27.2%) | 67 (72.8%) | 13 (22.8%) | 44 (77.2%) | 12 (34.3%) | 23 (65.7%) |
| (y)2 | 64 (56.1%) | 50 (43.9%) | 41 (55.4%) | 33 (44.6%) | 23 (57.5%) | 17 (42.5%) |
| (y)3 | 74 (54.0%) | 63 (46.0%) | 44 (58.7%) | 31 (41.3%) | 30 (48.4%) | 32 (51.6%) |
| (y)4 | 43 (70.5%) | 18 (29.5%) | 24 (63.2%) | 14 (36.8%) | 19 (82.6%) | 4 (17.4%) |
| Molecular subtype | ||||||
| CIN | 155 (50.3%) | 153 (49.7%) | 86 (47.8%) | 94 (52.2%) | 69 (53.9%) | 59 (46.1%) |
| MSI | 6 (16.2%) | 31 (83.8%) | 4 (15.4%) | 22 (84.6%) | 2 (18.2%) | 9 (81.8%) |
| GS | 31 (56.4%) | 24 (43.6%) | 23 (63.9%) | 13 (36.1%) | 8 (42.1%) | 11 (57.9%) |
| EBV | 10 (52.6%) | 9 (47.4%) | 5 (62.5%) | 3 (37.5%) | 5 (45.5%) | 6 (54.5%) |
| Localisation | ||||||
| Proximal | 90 (48.4%) | 96 (51.6%) | 50 (51.5%) | 47 (48.5%) | 40 (44.9%) | 49 (55.1%) |
| Corpus | 64 (51.2%) | 61 (48.8%) | 33 (47.1%) | 37 (52.9%) | 31 (56.4%) | 24 (43.6%) |
| Distal | 51 (51.5%) | 48 (48.5%) | 36 (50.7%) | 35 (49.3%) | 15 (53.6%) | 13 (46.4%) |
| Other | 19 (51.4%) | 18 (48.6%) | 12 (42.9%) | 16 (57.1%) | 7 (77.8%) | 2 (22.2%) |
UICC Union internationale contre le cancer, CIN chromosomal instability, MSI microsatellite instability, GS genomically stable, EBV Epstein–Barr virus-positive